A comparative study of a low-dose estradiol vaginal ring and conjugated estrogen cream for postmenopausal urogenital atrophy

Primary Care Update for Ob/Gyns

Volumn 4, Issue 3, 1997, Pages 109-115

  Bachmann, Gloria ^a   Notelovitz, Morris ^b   Nachtigall, Lila ^b   Birgerson, Lars ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BULLOUS SKIN DISEASE; CELL MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTODIAGNOSIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSURIA; EDEMA; ENDOMETRIUM BIOPSY; FEMALE; HEADACHE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; MYALGIA; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TOPICAL DRUG ADMINISTRATION; VAGINA ATROPHY;

EID: 0031010637     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(97)00001-2     Document Type: Article

References (13)

1. Carlstrom K, Karlgren E, Furuhjelm M, Ryd-Kjellen E. Effects of intravaginal estrogen treatment upon the vaginal absorption of conjugated equine estrogens. Maturitas 1982;4: 277-83.
2. Deutsch S, Ossowski R, Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981;139:967-8.
3. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency: a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-7.
4. Ellerington MC, Whitcroft SIJ, Whitehead MI. HRT: developments in therapy. Br Med Bull 1991;48: 401-25.
5. Haspels A, Luisi M, Kicovic P. Endocrinological and clinical investigations in postmenopausal women following administration of vaginal cream containing estriol. Maturitas 1981;3:321-7.
6. Holmgren P-A, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989;11:55-63.
7. Smith P. Estrogens and the urogenital tract studies on steroid hormone receptors and a clinical study of a new estradiol-releasing ring. Acta Obstet Gynecol Scand Suppl 1993; 157:1-26.
8. Vartianinen J, Wahlstrom T, Nilsson CG. Effects of a new 17 beta-estradiol releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17: 129-37.
9. Schmidt G, Andersson SB, Nordle O, Johansson C-J, Gunnarson PO. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994;38: 253-60.
10. Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-8.
11. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171;624-32.
12. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multi-center study of efficacy and safety of a continuous low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996; 174:85-92.
13. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145-54.